The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2020 | Gemtuzumab ozogamicin in frontline AML therapy
Juliette Lambert, MD, Versailles Hospital, Le Chesnay, France, outlines the final efficacy and safety updates from the open-label, Phase III ALFA-0701 trial (NCT00927498) of gemtuzumab ozogamicin for de novo acute myeloid leukemia (AML). Additionally, Dr Lambert discusses the use of gemtuzumab ozogamicin in clinical practice. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
